---
title: "Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Pharmacology questions"
description: "Pharmacology questions on Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does DATROWAY work (mechanism of action)? How is DATROWAY metabolized? What is the half-life of DATROWAY? What are the ingredients in DATROWAY? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Pharmacology questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Datroway](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true)

## Mechanism

<a id="datroway-mechanism"></a>

### How does DATROWAY work (mechanism of action)?

> “Datopotamab deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 
> IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following 
> binding to Trop-2 on cells, including tumor cells, datopotamab deruxtecan-dlnk undergoes internalization and intracellular 
> linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic 
> cell death.”

Source: [DATROWAY: Prescribing information, page 16, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=16)

> “DATROWAY is a specifically engineered Trop-2-directed antibody-drug conjugate<sup>1,2</sup>
> Designed to induce selective tumor cell death and reduce systemic exposureto the topoisomerase I inhibitor payload
> Trop-2-directed mAb<sup>1,2</sup>*
> Leverages Trop-2, a cell surface protein, to provide selective delivery of cytotoxic agent
> Tumor-selective cleavable linker<sup>1-3</sup>*<sup>†</sup>
> Attaches payload to the antibody
> Linker-payload is stable in plasma
> Linker is selectively cleaved by enzymes that are upregulated in tumor cells
> DXd payload<sup>1-4</sup>*<sup>†</sup>
> Potent topoisomerase I inhibitor payload with a short systemic half-life
> Upon release, membrane-permeable payload causes DNA damage and cell death, resulting in destruction of targeted tumor cells and neighboring cells present in the tumor microenvironment, known as the bystander antitumor effect
>
> <sup>*</sup>
> Information from laboratory studies suggests that this is how DATROWAY works.<sup>2</sup>
>
> <sup>†</sup>
> Based on animal data. The clinical relevance of these features is under investigation.<sup>2</sup>”

Source: [DATROWAY: Mechanism of Action (MOA), captured 2026-11-08](https://datrowayhcp.com/mechanism-of-action#:~:text=DATROWAY%20is%20a%20specifically%20engineered,of%20these%20features%20is%20under)

## Pharmacokinetics

<a id="datroway-metabolism"></a>

### How is DATROWAY metabolized?

> “Datopotamab deruxtecan-dlnk undergoes intracellular cleavage by lysosomal enzymes to release DXd. 
>
> The humanized Trop-2 IgG1 monoclonal antibody is expected to be degraded into small peptides and amino acids via 
> catabolic pathways in the same manner as endogenous IgG. 
>
> In vitro, DXd is primarily metabolized by CYP3A4.”

Source: [DATROWAY: Prescribing information, page 17, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=17)

<a id="datroway-half-life"></a>

### What is the half-life of DATROWAY?

> “The datopotamab deruxtecan-dlnk median elimination half-life (t1/2) is 4.8 days (1.0, 8.2) and the released DXd median 
> apparent t1/2 is approximately 5.5 days (3.2, 8.8). The estimated datopotamab deruxtecan-dlnk clearance is 0.6 (31.5%) 
> L/day.”

Source: [DATROWAY: Prescribing information, page 17, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=17)

## Components

<a id="datroway-ingredients"></a>

### What are the ingredients in DATROWAY?

> “DATROWAY (datopotamab deruxtecan-dlnk) for injection is a sterile, white to yellowish white, preservative-free 
> lyophilized powder in single-dose vials. Each vial delivers 100 mg of datopotamab deruxtecan-dlnk, L-histidine (3.88 mg), 
> L-histidine hydrochloride monohydrate (5.25 mg), polysorbate 80 (1.50 mg), and sucrose (450 mg).”

Source: [DATROWAY: Prescribing information, page 16, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=16)

## Related pages
- [Medical information: Datroway (datopotamab deruxtecan-dlnk): HR-positive HER2-negative breast cancer](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/access-and-coverage)
